A guide to interpretation of neuroimmunological biomarkers in the combined antiretroviral therapy-era of HIV central nervous system disease

References

• Price RW, Epstein LG, Becker JT, et al. Biomarkers of HIV-1 CNS infection and injury. Neurology. 2007;69:1781–1788.
   PubMed Web of Science ®Google Scholar
• Gisslen M, Hagberg L, Rosengren L, et al. Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers. J Neuroimmune Pharmacol. 2007;2:112–119.
   PubMed Web of Science ®Google Scholar
• Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69: 1789–1799.
   PubMed Web of Science ®Google Scholar
• Brew B. Principles of HIV neurology. HIV Neurology. Vol 1. New York: Oxford University Press; 2001:32–35.
   Google Scholar
• Robertson KR, Smurzynski M, Parsons TD, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS. 2007;21:1915–1921.
   PubMed Web of Science ®Google Scholar
• Dore GJ, Correll PK, Li Y, Kaldor JM, Cooper DA, Brew BJ. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS. 1999;13:1249–1253.
   PubMed Web of Science ®Google Scholar
• Brew BJ, Dore G. Decreasing incidence of CNS AIDS defining events associated with antiretroviral therapy. Neurology. 2000;55:1424.
   PubMed Web of Science ®Google Scholar
• Dore GJ, McDonald A, Li Y, Kaldor JM, Brew BJ. Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS. 2003;17:1539–1545.
   PubMed Web of Science ®Google Scholar
• Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008;65:65–70.
   PubMed Web of Science ®Google Scholar
• Budka H. The neuropathology of HIV-associated brain disease. In: Gendelman HE, Grant I, Everall IP, Lipton, SA, Swindells S, editors. The neurology of AIDS. 2nd ed. New York: Oxford University Press; 2005:375–391.
   Google Scholar
• Floyd E, McShane TM. Development and use of biomarkers in oncology drug development. Toxicol Pathol. 2004;32(Suppl 1):106–115.
   PubMedGoogle Scholar
• Giovannoni G. Multiple sclerosis cerebrospinal fluid biomarkers. Dis Markers. 2006;22:187–196.
   PubMed Web of Science ®Google Scholar
• Thompson EJ. Cerebrospinal fluid. J Neurol Neurosurg Psychiatry. 1995;59:349–357.
   Web of Science ®Google Scholar
• Brew BJ, Letendre SL. Biomarkers of HIV related central nervous system disease. Int Rev Psychiatry. 2008;20:73–88.
   PubMed Web of Science ®Google Scholar
• Brew BJ. Markers of AIDS dementia complex: the role of cerebrospinal fluid assays. AIDS. 2001;15:1883–1884.
   Web of Science ®Google Scholar
• Cysique LA, Maruff P, Brew BJ. Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. Neurology. 2006;66:1447–1450.
   PubMed Web of Science ®Google Scholar
• Brew BJ. Medical management of AIDS patients. Central and peripheral nervous system abnormalities. Med Clin North Am. 1992;76: 63–81.
   Google Scholar
• Brew BJ. Human immunodeficiency virus in brain and correlation with dementia. Ann Neurol. 1996;39:828–829.
   Web of Science ®Google Scholar
• Kamat A, Ravi V, Desai A, Satishchandra P, Satish KS, Kumar M. Estimation of virological and immunological parameters in subjects from South India infected with human immunodeficiency virus type 1 clade C and correlation of findings with occurrence of neurological disease. J Neurovirol. 2009;15:25–35.
   Web of Science ®Google Scholar
• Pulliam L, Gascon R, Stubblebine M, McGuire D, McGrath MS. Unique monocyte subset in patients with AIDS dementia. Lancet. 1997;349:692–695.
   PubMed Web of Science ®Google Scholar
• Kusdra L, McGuire D, Pulliam L. Changes in monocyte/macrophage neurotoxicity in the era of HAART: implications for HIV-associated dementia. AIDS. 2002;16:31–38.
   PubMed Web of Science ®Google Scholar
• Valcour VG, Shiramizu BT, Sithinamsuwan P, et al. HIV DNA and cognition in a Thai longitudinal HAART initiation cohort: the SEARCH 001 Cohort Study. Neurology. 2009;72:992–998.
   PubMed Web of Science ®Google Scholar
• Landmann R, Muller B, Zimmerli W. CD14, new aspects of ligand and signal diversity. Microbes Infect. 2000;2:295–304.
   PubMed Web of Science ®Google Scholar
• Lien E, Aukrust P, Sundan A, Muller F, Froland SS, Espevik T. Elevated levels of serum-soluble CD14 in human immunodeficiency virus type 1 (HIV-1) infection: correlation to disease progression and clinical events. Blood. 1998;92:2084–2092.
   PubMed Web of Science ®Google Scholar
• Nockher WA, Bergmann L, Scherberich JE. Increased soluble CD14 serum levels and altered CD14 expression of peripheral blood monocytes in HIV-infected patients. Clin Exp Immunol. 1994;98: 369–374.
   PubMed Web of Science ®Google Scholar
• Ryan LA, Zheng J, Brester M, et al. Plasma levels of soluble CD14 and tumor necrosis factor-alpha type II receptor correlate with cognitive dysfunction during human immunodeficiency virus type 1 infection. J Infect Dis. 2001;184:699–706.
   PubMed Web of Science ®Google Scholar
• Cauwels A, Frei K, Sansano S, et al. The origin and function of soluble CD14 in experimental bacterial meningitis. J Immunol. 1999;162:4762–4772.
   PubMed Web of Science ®Google Scholar
• Sun B, Abadjian L, Rempel H, Calosing C, Rothlind J, Pulliam L. Peripheral biomarkers do not correlate with cognitive impairment in highly active antiretroviral therapy-treated subjects with human immunodeficiency virus type 1 infection. J Neurovirol. 2010;16:115–124.
   PubMed Web of Science ®Google Scholar
• Brew BJ, Bhalla RB, Paul M, et al. Cerebrospinal fluid neopterin in human immunodeficiency virus type 1 infection. Ann Neurol. 1990;28: 556–560.
   PubMed Web of Science ®Google Scholar
• Hamerlinck FF. Neopterin: a review. Exp Dermatol. 1999;8:167–176.
   PubMed Web of Science ®Google Scholar
• Brew BJ, Dunbar N, Pemberton L, Kaldor J. Predictive markers of AIDS dementia complex: CD4 cell count and cerebrospinal fluid concentrations of beta 2-microglobulin and neopterin. J Infect Dis. 1996;174:294–298.
   PubMed Web of Science ®Google Scholar
• Abdulle S, Hagberg L, Svennerholm B, Fuchs D, Gisslen M. Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection. AIDS. 2002;16:2145–2149.
   PubMed Web of Science ®Google Scholar
• Heyes MP, Brew BJ, Martin A, et al. Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. Ann Neurol. 1991;29:202–209.
   PubMed Web of Science ®Google Scholar
• Behan WM, McDonald M, Darlington LG, Stone TW. Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin and deprenyl. Br J Pharmacol. 1999;128: 1754–1760.
   PubMed Web of Science ®Google Scholar
• Martin A, Heyes MP, Salazar AM, et al. Progressive slowing of reaction time and increasing cerebrospinal fluid concentrations of quinolinic acid in HIV-infected individuals. J Neuropsychiatry Clin Neurosci. 1992;4:270–279.
   PubMed Web of Science ®Google Scholar
• Valle M, Price RW, Nilsson A, Heyes M, Verotta D. CSF quinolinic acid levels are determined by local HIV infection: cross-sectional analysis and modelling of dynamics following antiretroviral therapy. Brain. 2004;127:1047–1060.
   PubMed Web of Science ®Google Scholar
• Glass JD, Fedor H, Wesselingh SL, McArthur JC. Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann Neurol. 1995;38:755–762.
   PubMed Web of Science ®Google Scholar
• Yoshioka M, Shapshak P, Sun NC, et al. Simultaneous detection of ferritin and HIV-1 in reactive microglia. Acta Neuropathol. 1992;84: 297–306.
   PubMed Web of Science ®Google Scholar
• Deisenhammer F, Miller RF, Brink NS, Harrison MJ, Thompson EJ. Cerebrospinal fluid ferritin in HIV infected patients with acute neurological episodes. Genitourin Med. 1997;73:181–183.
   Google Scholar
• Pemberton LA, Brew BJ. Cerebrospinal fluid S-100beta and its relationship with AIDS dementia complex. J Clin Virol. 2001;22:249–253.
   PubMed Web of Science ®Google Scholar
• Hu J, Ferreira A, van Eldik LJ. S100beta induces neuronal cell death through nitric oxide release from astrocytes. J Neurochem. 1997;69:2294–2301.
   PubMed Web of Science ®Google Scholar
• Woods SP, Iudicello JE, Dawson MS, Weber E, Grant I, Letendre SL. HIV-associated deficits in action (verb) generation may reflect astrocytosis. J Clin Exp Neuropsychol. 2009:1–6.
   Web of Science ®Google Scholar
• Oppenheim JJ, Ruscetti FW. Cytokines. In: Parslow TG, Stites DP, Terr AI, Imboden JB, editors. Medical immunology. New York: Lange Medical Books/McGraw-Hill Medical Publishing; 2001.
   Google Scholar
• Gallo P, Frei K, Rordorf C, Lazdins J, Tavolato B, Fontana A. Human immunodeficiency virus type 1 (HIV-1) infection of the central nervous system: an evaluation of cytokines in cerebrospinal fluid. J Neuroimmunol. 1989;23:109–116.
   PubMed Web of Science ®Google Scholar
• Perrella O, Carrieri PB, Guarnaccia D, Soscia M. Cerebrospinal fluid cytokines in AIDS dementia complex. J Neurol. 1992;239:387–388.
   PubMed Web of Science ®Google Scholar
• Gallo P, Laverda AM, de Rossi A, et al. Immunological markers in the cerebrospinal fluid of HIV-1-infected children. Acta Paediatr Scand. 1991;80:659–666.
   PubMed Web of Science ®Google Scholar
• Laverda AM, Gallo P, de Rossi A, et al. Cerebrospinal fluid analysis in HIV-1-infected children: immunological and virological findings before and after AZT therapy. Acta Paediatr. 1994;83:1038–1042.
   PubMed Web of Science ®Google Scholar
• Perrella O, Carreiri PB, Perrella A, et al. Transforming growth factor beta-1 and interferon-alpha in the AIDS dementia complex (ADC): possible relationship with cerebral viral load? Eur Cytokine Netw. 2001;12:51–55.
   PubMed Web of Science ®Google Scholar
• Rieckmann P, Albrecht M, Ehrenreich H, Weber T, Michel U. Semi-quantitative analysis of cytokine gene expression in blood and cerebrospinal fluid cells by reverse transcriptase polymerase chain reaction. Res Exp Med (Berl). 1995;195:17–29.
   PubMedGoogle Scholar
• Torre D, Zeroli C, Ferraro G, et al. Cerebrospinal fluid levels of IL-6 in patients with acute infections of the central nervous system. Scand J Infect Dis. 1992;24:787–791.
   PubMed Web of Science ®Google Scholar
• Griffin DE, McArthur JC, Cornblath DR. Neopterin and interferon-gamma in serum and cerebrospinal fluid of patients with HIV-associated neurologic disease. Neurology. 1991;41:69–74.
   PubMed Web of Science ®Google Scholar
• Tyor WR, Glass JD, Griffin JW, et al. Cytokine expression in the brain during the acquired immunodeficiency syndrome. Ann Neurol. 1992;31:349–360.
   PubMed Web of Science ®Google Scholar
• Kolb SA, Sporer B, Lahrtz F, Koedel U, Pfister HW, Fontana A. Identification of a T cell chemotactic factor in the cerebrospinal fluid of HIV-1-infected individuals as interferon-gamma inducible protein 10. J Neuroimmunol. 1999;93:172–181.
   PubMed Web of Science ®Google Scholar
• von Giesen HJ, Jander S, Koller H, Arendt G. Serum and cerebrospinal fluid levels of interleukin-18 in human immunodeficiency virus type 1-associated central nervous system disease. J Neurovirol. 2004;10:383–386.
   PubMed Web of Science ®Google Scholar
• Kelder W, McArthur JC, Nance-Sproson T, McClernon D, Griffin DE. Beta-chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia. Ann Neurol. 1998;44:831–835.
   PubMed Web of Science ®Google Scholar
• Gallo P, Sivieri S, Rinaldi L, et al. Intrathecal synthesis of interleukin-10 (IL-10) in viral and inflammatory diseases of the central nervous system. J Neurol Sci. 1994;126:49–53.
   PubMed Web of Science ®Google Scholar
• Cosman D. Hematopoietic cell growth factors and their receptors. In: Whetten ADI, DN. Blood Cell Biochemistry. Vol 7. New York: Plenum PRess; 1996.
   Google Scholar
• Gruss HJ, Dower SK. Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood. 1995;85:3378–3404.
   PubMed Web of Science ®Google Scholar
• Armitage RJ. Tumor necrosis factor receptor superfamily members and their ligands. Curr Opin Immunol. 1994;6:407–413.
   PubMed Web of Science ®Google Scholar
• Baker SJ, Reddy EP. Transducers of life and death: TNF receptor superfamily and associated proteins. Oncogene. 1996;12:1–9.
   PubMed Web of Science ®Google Scholar
• Lotz M, Terkeltaub R, Villiger PM. Cartilage and joint inflammation. Regulation of IL-8 expression by human articular chondrocytes. J Immunol. 1992;148:466–473.
   PubMed Web of Science ®Google Scholar
• Ware CF, VanArsdale S, VanArsdale TL. Apoptosis mediated by the TNF-related cytokine and receptor families. J Cell Biochem. 1996;60:47–55.
   PubMed Web of Science ®Google Scholar
• Zoumpourlis V, Eliopoulos AG, Spandidos DA. Transcriptional activation of the human immunodeficiency virus long terminal repeat sequences by tumor necrosis factor. Anticancer Res. 1992;12:2065–2068.
   PubMed Web of Science ®Google Scholar
• Mastroianni CM, Paoletti F, Valenti C, Vullo V, Jirillo E, Delia S. Tumour necrosis factor (TNF-alpha) and neurological disorders in HIV infection. J Neurol Neurosurg Psychiatry. 1992;55:219–221.
   PubMed Web of Science ®Google Scholar
• Achim CL, Heyes MP, Wiley CA. Quantitation of human immunodeficiency virus, immune activation factors, and quinolinic acid in AIDS brains. J Clin Invest. 1993;91:2769–2775.
   PubMed Web of Science ®Google Scholar
• Wesselingh SL, Glass J, McArthur JC, Griffin JW, Griffin DE. Cytokine dysregulation in HIV-associated neurological disease. Adv Neuroimmunol. 1994;4:199–206.
   PubMedGoogle Scholar
• Nolting T, Lindecke A, Koutsilieri E, et al. Measurement of soluble inflammatory mediators in cerebrospinal fluid of human immunodeficiency virus-positive patients at distinct stages of infection by solid-phase protein array. J Neurovirol. 2009;15:390–400.
   Web of Science ®Google Scholar
• Mastroianni CM, Paoletti F, Massetti AP, Falciano M, Vullo V. Elevated levels of tumor necrosis factor (TNF) in the cerebrospinal fluid from patients with HIV-associated neurological disorders. Acta Neurol (Napoli). 1990;12:66–67.
   PubMedGoogle Scholar
• Sevigny JJ, Albert SM, McDermott MP, et al. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology. 2004;63:2084–2090.
   PubMed Web of Science ®Google Scholar
• Lafeuillade A, Poggi C, Pellegrino P, Corti K, Profizi N, Sayada C. HIV-1 replication in the plasma and cerebrospinal fluid. Infection. 1996;24:367–371.
   PubMed Web of Science ®Google Scholar
• Franciotta DM, Melzi d’Eril GL, Bono G, Brustia R, Ruberto G, Pagani I. Tumor necrosis factor alpha levels in serum and cerebrospinal fluid of patients with AIDS. Funct Neurol. 1992;7:35–38.
   PubMedGoogle Scholar
• Gendelman HE, Zheng J, Coulter CL, et al. Suppression of inflammatory neurotoxins by highly active antiretroviral therapy in human immunodeficiency virus-associated dementia. J Infect Dis. 1998;178:1000–1007.
   PubMed Web of Science ®Google Scholar
• Gisolf EH, van Praag RM, Jurriaans S, et al. Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr. 2000;25:426–433.
   PubMed Web of Science ®Google Scholar
• Letendre S, Buzzel M, Marquie-Beck J, Cherner M, Ances B, Ellis RJ, ATH Group: the effects of antiretroviral use on cerebrospinal fluid biomarkers and neuropsychological performance. In 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO; 2006.
   Google Scholar
• Campbell IL, Krucker T, Steffensen S, et al. Structural and functional neuropathology in transgenic mice with CNS expression of IFN-alpha. Brain Res. 1999;835:46–61.
   PubMed Web of Science ®Google Scholar
• Sas AR, Bimonte-Nelson H, Smothers CT, Woodward J, Tyor WR. Interferon-alpha causes neuronal dysfunction in encephalitis. J Neurosci. 2009;29:3948–3955.
   Web of Science ®Google Scholar
• Krivine A, Force G, Servan J, et al. Measuring HIV-1 RNA and interferon-alpha in the cerebrospinal fluid of AIDS patients: insights into the pathogenesis of AIDS Dementia Complex. J Neurovirol. 1999;5:500–506.
   PubMed Web of Science ®Google Scholar
• Rho MB, Wesselingh S, Glass JD, et al. A potential role for interferon-alpha in the pathogenesis of HIV-associated dementia. Brain Behav Immun. 1995;9:366–377.
   PubMed Web of Science ®Google Scholar
• Fuchs D, Forsman A, Hagberg L, et al. Immune activation and decreased tryptophan in patients with HIV-1 infection. J Interferon Res. 1990;10:599–603.
   PubMedGoogle Scholar
• Shacklett BL, Cox CA, Wilkens DT, et al. Increased adhesion molecule and chemokine receptor expression on CD8+ T cells trafficking to cerebrospinal fluid in HIV-1 infection. J Infect Dis. 2004;189:2202–2212.
   PubMed Web of Science ®Google Scholar
• Probasco JC, Deeks SG, Lee E, et al. Cerebrospinal fluid in HIV-1 systemic viral controllers: absence of HIV-1 RNA and intrathecal inflammation. AIDS. 2010.
   Web of Science ®Google Scholar
• Cinque P, Bestetti A, Marenzi R, et al. Cerebrospinal fluid interferon-gamma-inducible protein 10 (IP-10, CXCL10) in HIV-1 infection. J Neuroimmunol. 2005;168:154–163.
   PubMed Web of Science ®Google Scholar
• Weiss JM, Nath A, Major EO, Berman JW. HIV-1 Tat induces monocyte chemoattractant protein-1-mediated monocyte transmigration across a model of the human blood-brain barrier and up-regulates CCR5 expression on human monocytes. J Immunol. 1999;163:2953–2959.
   PubMed Web of Science ®Google Scholar
• Conant K, Garzino-Demo A, Nath A, et al. Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. Proc Natl Acad Sci U S A. 1998;95: 3117–3121.
   PubMed Web of Science ®Google Scholar
• Guillemin GJ, Williams KR, Smith DG, Smythe GA, Croitoru-Lamoury J, Brew BJ. Quinolinic acid in the pathogenesis of Alzheimer’s disease. Adv Exp Med Biol. 2003;527:167–176.
   Web of Science ®Google Scholar
• Sanders VJ, Pittman CA, White MG, Wang G, Wiley CA, Achim CL. Chemokines and receptors in HIV encephalitis. AIDS. 1998;12:1021–1026.
   PubMed Web of Science ®Google Scholar
• Monteiro de Almeida S, Letendre S, Zimmerman J, Lazzaretto D, McCutchan A, Ellis R. Dynamics of monocyte chemoattractant protein type one (MCP-1) and HIV viral load in human cerebrospinal fluid and plasma. J Neuroimmunol. 2005;169:144–152.
   PubMed Web of Science ®Google Scholar
• Avison MJ, Nath A, Greene-Avison R, et al. Inflammatory changes and breakdown of microvascular integrity in early human immunodeficiency virus dementia. J Neurovirol. 2004;10:223–232.
   PubMed Web of Science ®Google Scholar
• Bernasconi S, Cinque P, Peri G, et al. Selective elevation of monocyte chemotactic protein-1 in the cerebrospinal fluid of AIDS patients with cytomegalovirus encephalitis. J Infect Dis. 1996;174:1098–1101.
   PubMed Web of Science ®Google Scholar
• Cinque P, Vago L, Mengozzi M, et al. Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication. AIDS. 1998;12:1327–1332.
   PubMed Web of Science ®Google Scholar
• Sozzani S, Introna M, Bernasconi S, et al. MCP-1 and CCR2 in HIV infection: regulation of agonist and receptor expression. J Leukoc Biol. 1997;62:30–33.
   PubMed Web of Science ®Google Scholar
• He J, Chen Y, Farzan M, et al. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature. 1997;385:645–649.
   PubMed Web of Science ®Google Scholar
• Sasseville VG, Smith MM, Mackay CR, et al. Chemokine expression in simian immunodeficiency virus-induced AIDS encephalitis. Am J Pathol. 1996;149:1459–1467.
   PubMed Web of Science ®Google Scholar
• Westmoreland SV, Rottman JB, Williams KC, Lackner AA, Sasseville VG. Chemokine receptor expression on resident and inflammatory cells in the brain of macaques with simian immunodeficiency virus encephalitis. Am J Pathol. 1998;152:659–665.
   PubMed Web of Science ®Google Scholar
• Hesselgesser J, Horuk R. Chemokine and chemokine receptor expression in the central nervous system. J Neurovirol. 1999;5:13–26.
   PubMed Web of Science ®Google Scholar
• Schmidtmayerova H, Nottet HS, Nuovo G, et al. Human immunodeficiency virus type 1 infection alters chemokine beta peptide expression in human monocytes: implications for recruitment of leukocytes into brain and lymph nodes. Proc Natl Acad Sci U S A. 1996;93: 700–704.
   PubMed Web of Science ®Google Scholar
• Letendre SL, Lanier ER, McCutchan JA. Cerebrospinal fluid beta chemokine concentrations in neurocognitively impaired individuals infected with human immunodeficiency virus type 1. J Infect Dis. 1999;180:310–319.
   PubMed Web of Science ®Google Scholar
• Re DB, Przedborski S. Fractalkine: moving from chemotaxis to neuroprotection. Nat Neurosci. 2006;9:859–861.
   PubMed Web of Science ®Google Scholar
• Erichsen D, Lopez AL, Peng H, et al. Neuronal injury regulates fractalkine: relevance for HIV-1 associated dementia. J Neuroimmunol. 2003;138:144–155.
   PubMed Web of Science ®Google Scholar
• Sporer B, Kastenbauer S, Koedel U, Arendt G, Pfister HW. Increased intrathecal release of soluble fractalkine in HIV-infected patients. AIDS Res Hum Retroviruses. 2003;19:111–116.
   PubMed Web of Science ®Google Scholar
• Letendre S, Zheng J, Yiannoutsos C, et al. Chemokines correlate with cerebral metabolites on magnetic resonance spectroscopy: a sub study of ACTG 301 and 700. 11th COnference on Retroviruses and Opportunistic Infections. San Francisco, CA; 2004.
   Google Scholar
• Scorziello A, Florio T, Bajetto A, Thellung S, Schettini G. TGF-beta1 prevents gp120-induced impairment of Ca2+ homeostasis and rescues cortical neurons from apoptotic death. J Neurosci Res. 1997;49:600–607.
   PubMed Web of Science ®Google Scholar
• Johnson MD, Kim P, Tourtellotte W, Federspiel CF. Transforming growth factor beta and monocyte chemotactic protein-1 are elevated in cerebrospinal fluid of immunocompromised patients with HIV-1 infection. J Neuro AIDS. 2004;2:33–43.
   PubMedGoogle Scholar
• Nebuloni M, Cinque P, Sidenius N, et al. Expression of the urokinase plasminogen activator receptor (uPAR) and its ligand (uPA) in brain tissues of human immunodeficiency virus patients with opportunistic cerebral diseases. J Neurovirol. 2009;15:99–107.
   Web of Science ®Google Scholar
• Cinque P, Nebuloni M, Santovito ML, et al. The urokinase receptor is overexpressed in the AIDS dementia complex and other neurological manifestations. Ann Neurol. 2004;55:687–694.
   PubMed Web of Science ®Google Scholar
• Brew BJ, Pemberton L, Cunningham P, Law MG. Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage. J Infect Dis. 1997;175:963–966.
   PubMed Web of Science ®Google Scholar
• Ellis RJ, Hsia K, Spector SA, et al. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group. Ann Neurol. 1997;42:679–688.
   PubMed Web of Science ®Google Scholar
• Karlsson U, Antonsson L, Repits J, et al. Mode of coreceptor use by R5 HIV type 1 correlates with disease stage: a study of paired plasma and cerebrospinal fluid isolates. AIDS Res Hum Retroviruses. 2009;25: 1297–1305.
   Web of Science ®Google Scholar
• McArthur JC, McClernon DR, Cronin MF, et al. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol. 1997;42:689–698.
   PubMed Web of Science ®Google Scholar
• Ellis RJ, Gamst AC, Capparelli E, et al. Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources. Neurology. 2000;54:927–936.
   PubMed Web of Science ®Google Scholar
• Ellis RJ, Moore DJ, Childers ME, et al. Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. Arch Neurol. 2002;59:923–928.
   PubMedGoogle Scholar
• Cysique LA, Maruff P, Brew BJ. Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. Neurology. 2006;66:1447–1450.
   PubMed Web of Science ®Google Scholar
• Shiramizu B, Lau E, Tamamoto A, Uniatowski J, Troelstrup D. Feasibility assessment of cerebrospinal fluid from HIV-1-infected children for HIV proviral DNA and monocyte chemoattractant protein 1 alleles. J Investig Med. 2006;54:468–472.
   PubMed Web of Science ®Google Scholar
• Cherner M, Letendre S, Heaton RK, et al. Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine. Neurology. 2005;64:1343–1347.
   PubMed Web of Science ®Google Scholar
• Letendre SL, Cherner M, Ellis RJ, et al. The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: biological correlates of disease. AIDS. 2005;19(Suppl 3):S72–S78.
   PubMed Web of Science ®Google Scholar
• Riedel DJ, Pardo CA, McArthur J, Nath A. Therapy Insight: CNS manifestations of HIV-associated immune reconstitution inflammatory syndrome. Nat Clin Pract Neurol. 2006;2:557–565.
   PubMedGoogle Scholar
• Shiramizu B, Gartner S, Williams A, et al. Circulating proviral HIV DNA and HIV-associated dementia. AIDS. 2005;19:45–52.
   PubMed Web of Science ®Google Scholar
• Shiramizu B, Ratto-Kim S, Sithinamsuwan P, et al. HIV DNA and dementia in treatment-naive HIV-1-infected individuals in Bangkok, Thailand. Int J Med Sci. 2007;4:13–18.
   Google Scholar
• Crews L, Patrick C, Achim CL, Everall IP, Masliah E. Molecular pathology of neuro-AIDS (CNS-HIV). Int J Mol Sci. 2009;10:1045–1063.
   PubMed Web of Science ®Google Scholar
• Griffin DE, Wesselingh SL, McArthur JC. Elevated central nervous system prostaglandins in human immunodeficiency virus-associated dementia. Ann Neurol. 1994;35:592–597.
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Miller RF, Heales SJ, Land JM, Harrison MJ, Thompson EJ. Elevated cerebrospinal fluid and serum nitrate and nitrite levels in patients with central nervous system complications of HIV-1 infection: a correlation with blood-brain-barrier dysfunction. J Neurol Sci. 1998;156:53–58.
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Heales SJ, Silver NC, et al. Raised serum nitrate and nitrite levels in patients with multiple sclerosis. J Neurol Sci. 1997;145:77–81.
   PubMed Web of Science ®Google Scholar
• Milstien S, Sakai N, Brew BJ, et al. Cerebrospinal fluid nitrite/nitrate levels in neurologic diseases. J Neurochem. 1994;63:1178–1180.
   PubMed Web of Science ®Google Scholar
• Li W, Malpica-Llanos TM, Gundry R, et al. Nitrosative stress with HIV dementia causes decreased L-prostaglandin D synthase activity. Neurology. 2008;70:1753–1762.
   PubMed Web of Science ®Google Scholar
• Epstein LG, Gelbard HA. HIV-1-induced neuronal injury in the developing brain. J Leukoc Biol. 1999;65:453–457.
   PubMed Web of Science ®Google Scholar
• Bazan NG, Packard MG, Teather L, Allan G. Bioactive lipids in excitatory neurotransmission and neuronal plasticity. Neurochem Int. 1997;30:225–231.
   PubMed Web of Science ®Google Scholar
• Bito H, Nakamura M, Honda Z, et al. Platelet-activating factor (PAF) receptor in rat brain: PAF mobilizes intracellular Ca2+ in hippocampal neurons. Neuron. 1992;9:285–294.
   PubMed Web of Science ®Google Scholar
• Franconi F, Miceli M, de Montis MG, Crisafi EL, Bennardini F, Tagliamonte A. NMDA receptors play an anti-aggregating role in human platelets. Thromb Haemost. 1996;76:84–87.
   PubMed Web of Science ®Google Scholar
• Tsoupras AB, Chini M, Tsogas N, et al. Anti-platelet-activating factor effects of highly active antiretroviral therapy (HAART): a new insight in the drug therapy of HIV infection? AIDS Res Hum Retroviruses. 2008;24:1079–1086.
   PubMed Web of Science ®Google Scholar
• Eggert D, Dash PK, Serradji N, et al. Development of a platelet-activating factor antagonist for HIV-1 associated neurocognitive disorders. J Neuroimmunol. 2009;213:47–59.
   Web of Science ®Google Scholar
• Marshall DW, Brey RL, Butzin CA, Lucey DR, Abbadessa SM, Boswell RN. CSF changes in a longitudinal study of 124 neurologically normal HIV-1-infected US. Air Force personnel. J Acquir Immune Defic Syndr. 1991;4:777–781.
   PubMed Web of Science ®Google Scholar
• Norgren N, Rosengren L, Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Res. 2003;987:25–31.
   PubMed Web of Science ®Google Scholar
• Abdulle S, Mellgren A, Brew BJ, et al. CSF neurofilament protein (NFL) – a marker of active HIV-related neurodegeneration. J Neurol. 2007;254:1026–1032.
   PubMed Web of Science ®Google Scholar
• Gisslen M, Rosengren L, Hagberg L, Deeks SG, Price RW. Cerebrospinal fluid signs of neuronal damage after antiretroviral treatment interruption in HIV-1 infection. AIDS Res Ther. 2005;2:6.
   PubMedGoogle Scholar
• Gisslen M, Hagberg L, Brew BJ, Cinque P, Price RW, Rosengren L. Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complex. J Infect Dis. 2007;195:1774–1778.
   PubMed Web of Science ®Google Scholar
• Mellgren A, Price RW, Hagberg L, Rosengren L, Brew BJ, Gisslen M. Antiretroviral treatment reduces increased CSF neurofilament protein (NFL) in HIV-1 infection. Neurology. 2007;69:1536–1541.
   PubMed Web of Science ®Google Scholar
• Brettschneider J, Petzold A, Schottle D, Claus A, Riepe M, Tumani H. The neurofilament heavy chain (NfH) in the cerebrospinal fluid diagnosis of Alzheimer’s disease. Dement Geriatr Cogn Disord. 2006;21:291–295.
   PubMed Web of Science ®Google Scholar
• Petzold A, Eikelenboom MJ, Gveric D, et al. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain. 2002;125:1462–1473.
   PubMed Web of Science ®Google Scholar
• Petzold A, Hinds N, Murray NM, et al. CSF neurofilament levels: a potential prognostic marker in Guillain-Barre syndrome. Neurology. 2006;67:1071–1073.
   PubMed Web of Science ®Google Scholar
• Gisslen M, Krut J, Andreasson U, et al. Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. BMC Neurol. 2009;9:63.
   PubMed Web of Science ®Google Scholar
• Andreasen N, Sjogren M, Blennow K. CSF markers for Alzheimer’s disease: total tau, phospho-tau and Abeta42. World J Biol Psychiatry. 2003;4:147–155.
   PubMed Web of Science ®Google Scholar
• Brew BJ, Pemberton L, Blennow K, Wallin A, Hagberg L. CSF amyloid beta42 and tau levels correlate with AIDS dementia complex. Neurology. 2005;65:1490–1492.
   PubMed Web of Science ®Google Scholar
• Clifford DB, Fagan AM, Holtzman DM, et al. CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease. Neurology. 2009;73:1982–1987.
   PubMed Web of Science ®Google Scholar
• Bandaru VV, McArthur JC, Sacktor N, et al. Associative and predictive biomarkers of dementia in HIV-1-infected patients. Neurology. 2007;68:1481–1487.
   Web of Science ®Google Scholar
• Abdulle S, Hagberg L, Gisslen M. Effects of antiretroviral treatment on blood-brain barrier integrity and intrathecal immunoglobulin production in neuroasymptomatic HIV-1-infected patients. HIV Med. 2005;6:164–169.
   PubMed Web of Science ®Google Scholar
• Hall CD, Snyder CR, Robertson KR, et al. Cerebrospinal fluid analysis in human immunodeficiency virus infection. Ann Clin Lab Sci. 1992;22:139–143.
   PubMed Web of Science ®Google Scholar
• Singer EJ, Syndulko K, Fahy-Chandon B, Schmid P, Conrad A, Tourtellotte WW. Intrathecal IgG synthesis and albumin leakage are increased in subjects with HIV-1 neurologic disease. J Acquir Immune Defic Syndr. 1994;7:265–271.
   PubMed Web of Science ®Google Scholar
• Andersson LM, Hagberg L, Fuchs D, Svennerholm B, Gisslen M. Increased blood-brain barrier permeability in neuro-asymptomatic HIV-1-infected individuals – correlation with cerebrospinal fluid HIV-1 RNA and neopterin levels. J Neurovirol. 2001;7:542–547.
   PubMed Web of Science ®Google Scholar
• Sporer B, Koedel U, Paul R, Eberle J, Arendt G, Pfister HW. Vascular endothelial growth factor (VEGF) is increased in serum, but not in cerebrospinal fluid in HIV associated CNS diseases. J Neurol Neurosurg Psychiatry. 2004;75:298–300.
   PubMed Web of Science ®Google Scholar
• Huang SH, Jong AY. Cellular mechanisms of microbial proteins contributing to invasion of the blood-brain barrier. Cell Microbiol. 2001;3:277–287.
   PubMed Web of Science ®Google Scholar
• Heidenreich F, Arendt G, Jander S, Jablonowski H, Stoll G. Serum and cerebrospinal fluid levels of soluble intercellular adhesion molecule 1 (sICAM-1) in patients with HIV-1 associated neurological diseases. J Neuroimmunol. 1994;52:117–126.
   PubMed Web of Science ®Google Scholar
• Rieckmann P, Nunke K, Burchhardt M, et al. Soluble intercellular adhesion molecule-1 in cerebrospinal fluid: an indicator for the inflammatory impairment of the blood-cerebrospinal fluid barrier. J Neuroimmunol. 1993;47:133–140.
   PubMed Web of Science ®Google Scholar
• Rosenberg GA. Matrix metalloproteinases in neuroinflammation. Glia. 2002;39:279–291.
   PubMed Web of Science ®Google Scholar
• Sporer B, Paul R, Koedel U, et al. Presence of matrix metalloproteinase-9 activity in the cerebrospinal fluid of human immunodeficiency virus-infected patients. J Infect Dis. 1998;178:854–857.
   PubMed Web of Science ®Google Scholar
• Conant K, McArthur JC, Griffin DE, Sjulson L, Wahl LM, Irani DN. Cerebrospinal fluid levels of MMP-2, 7, and 9 are elevated in association with human immunodeficiency virus dementia. Ann Neurol. 1999;46:391–398.
   PubMed Web of Science ®Google Scholar
• Liuzzi GM, Mastroianni CM, Santacroce MP, et al. Increased activity of matrix metalloproteinases in the cerebrospinal fluid of patients with HIV-associated neurological diseases. J Neurovirol. 2000; 6:156–163.
   PubMed Web of Science ®Google Scholar
• Rozek W, Ricardo-Dukelow M, Holloway S, et al. Cerebrospinal fluid proteomic profiling of HIV-1-infected patients with cognitive impairment. J Proteome Res. 2007;6:4189–4199.
   PubMed Web of Science ®Google Scholar
• Laspiur JP, Anderson ER, Ciborowski P, et al. CSF proteomic fingerprints for HIV-associated cognitive impairment. J Neuroimmunol. 2007;192:157–170.
   PubMed Web of Science ®Google Scholar